The Leiomyosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Leiomyosarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued products.
GlobalData tracks 65 drugs in development for Leiomyosarcoma by 55 companies/universities/institutes. The top development phase for Leiomyosarcoma is phase ii with 35 drugs in that stage. The Leiomyosarcoma pipeline has 63 drugs in development by companies and two by universities/ institutes. Some of the companies in the Leiomyosarcoma pipeline products market are: AstraZeneca, Pharma Mar and Merck.
The key targets in the Leiomyosarcoma pipeline products market include Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, and Programmed Cell Death 1 Ligand 1.
The key mechanisms of action in the Leiomyosarcoma pipeline product include Programmed Cell Death Protein 1 Antagonist with seven drugs in Phase II. The Leiomyosarcoma pipeline products include 14 routes of administration with the top ROA being Intravenous and ten key molecule types in the Leiomyosarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Leiomyosarcoma overview
Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure, and radiation exposure. Treatment includes chemotherapy, radiation therapy, and surgery.
For a complete picture of Leiomyosarcoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
